Talinolol
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461125

CAS#: 57460-41-0

Description: Talinolol is a beta(1)-adrenergic receptor antagonist and a probe drug for P-glycoprotein (P-gp) activity in humans.

Chemical Structure

img
Talinolol
CAS# 57460-41-0
Instruction

Theoretical Analysis

MedKoo Cat#: 461125
Name: Talinolol
CAS#: 57460-41-0
Chemical Formula: C20H33N3O3
Exact Mass: 363.25
Molecular Weight: 363.500
Elemental Analysis: C, 66.08; H, 9.15; N, 11.56; O, 13.20

Price and Availability

Size Price Availability Quantity
5mg USD 330
10mg USD 570
Bulk inquiry

Synonym: Talinolol; Cordanum;

IUPAC/Chemical Name: 1-(4-(3-(tert-butylamino)-2-hydroxypropoxy)phenyl)-3-cyclohexylurea

InChi Key: MXFWWQICDIZSOA-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H33N3O3/c1-20(2,3)21-13-17(24)14-26-18-11-9-16(10-12-18)23-19(25)22-15-7-5-4-6-8-15/h9-12,15,17,21,24H,4-8,13-14H2,1-3H3,(H2,22,23,25)

SMILES Code: CC(C)(NCC(COc1ccc(NC(NC2CCCCC2)=O)cc1)O)C

Appearance: Solid powder

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 363.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Nguyen MA, Staubach P, Tamai I, Langguth P. High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans. Eur J Pharm Sci. 2015 Feb 20;68:36-42. doi: 10.1016/j.ejps.2014.12.001. Epub 2014 Dec 5. PubMed PMID: 25486333.

2: Yan M, Fang PF, Li HD, Xu P, Liu YP, Wang F, Cai HL, Tan QY. Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers. Eur J Clin Pharmacol. 2013 Mar;69(3):515-21. doi: 10.1007/s00228-012-1391-6. Epub 2012 Sep 15. PubMed PMID: 22983284.

3: Long B, Su YQ, Xia Y, Zou YY, Tang B, Chen ZJ, Lin Y. No sex difference in overall P-glycoprotein activity as assessed by talinolol disposition in humans. Int J Clin Pharmacol Ther. 2016 Mar;54(3):157-62. doi: 10.5414/CP202477. PubMed PMID: 26784939.

4: Mohsin K, Al-Qahtani S, Alanazi FK. Rapid and sensitive bioanalytical stability-indicating method for quantification of talinolol, a selective β1 adrenoceptor antagonist in lipid based formulations using ultrafast UHPLC systems. Acta Pol Pharm. 2014 Sep-Oct;71(5):737-45. PubMed PMID: 25362802.

5: He X, Mo L, Li ZY, Tan ZR, Chen Y, Ouyang DS. Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism. Xenobiotica. 2012 Dec;42(12):1248-54. doi: 10.3109/00498254.2012.697590. Epub 2012 Jun 22. PubMed PMID: 22725663.

6: Matthaei J, Tzvetkov MV, Gal V, Sachse-Seeboth C, Sehrt D, Hjelmborg JB, Hofmann U, Schwab M, Kerb R, Brockmöller J. Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters. Genome Med. 2016 Nov 8;8(1):119. PubMed PMID: 27825374; PubMed Central PMCID: PMC5101708.

7: Nguyen MA, Staubach P, Wolffram S, Langguth P. Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans - Implications for the evaluation of transporter-mediated flavonoid-drug interactions. Eur J Pharm Sci. 2014 Sep 30;61:54-60. doi: 10.1016/j.ejps.2014.01.003. Epub 2014 Jan 25. PubMed PMID: 24472704.

8: Teja A, Musmade PB, Khade AB, Dengale SJ. Simultaneous improvement of solubility and permeability by fabricating binary glassy materials of Talinolol with Naringin: Solid state characterization, in-vivo in-situ evaluation. Eur J Pharm Sci. 2015 Oct 12;78:234-44. doi: 10.1016/j.ejps.2015.08.002. Epub 2015 Aug 5. PubMed PMID: 26253355.

9: Shakeel F, Haq N, Alanazi FK, Alsarra IA. Surface-adsorbed reverse micelle-loaded solid self-nanoemulsifying drug delivery system of talinolol. Pharm Dev Technol. 2016 Mar;21(2):131-9. doi: 10.3109/10837450.2014.971379. Epub 2014 Oct 16. PubMed PMID: 25318634.

10: Li Y, Shirasaka Y, Langguth P, Tamai I. Quantitation of talinolol in rat plasma by LC-MS-MS. J Chromatogr Sci. 2010 May-Jun;48(5):367-70. PubMed PMID: 20515530.

11: Shirasaka Y, Kuraoka E, Spahn-Langguth H, Nakanishi T, Langguth P, Tamai I. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther. 2010 Jan;332(1):181-9. doi: 10.1124/jpet.109.159756. Epub 2009 Sep 24. PubMed PMID: 19779132.

12: Kagan L, Dreifinger T, Mager DE, Hoffman A. Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats. Drug Metab Dispos. 2010 Sep;38(9):1560-6. doi: 10.1124/dmd.110.033019. Epub 2010 Jun 10. PubMed PMID: 20538723.

13: Elgart A, Cherniakov I, Aldouby Y, Domb AJ, Hoffman A. Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol. Pharm Res. 2013 Dec;30(12):3029-44. doi: 10.1007/s11095-013-1063-y. Epub 2013 May 18. PubMed PMID: 23686373.

14: Pathak SM, Udupa N. Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin. Biopharm Drug Dispos. 2010 Mar;31(2-3):202-14. doi: 10.1002/bdd.703. PubMed PMID: 20238375.

15: Chankvetadze L, Servais AC, Fillet M, Salgado A, Crommen J, Chankvetadze B. Comparative enantioseparation of talinolol in aqueous and non-aqueous capillary electrophoresis and study of related selector-selectand interactions by nuclear magnetic resonance spectroscopy. J Chromatogr A. 2012 Dec 7;1267:206-16. doi: 10.1016/j.chroma.2012.08.063. Epub 2012 Aug 27. PubMed PMID: 22964050.

16: Zeng Y, He FY, He YJ, Dai LL, Fan L, Zhou HH. Effect of bifendate on the pharmacokinetics of talinolol in healthy subjects. Xenobiotica. 2009 Nov;39(11):844-9. doi: 10.3109/00498250903111870. PubMed PMID: 19845435.

17: Han Y, Guo D, Chen Y, Tan ZR, Zhou HH. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica. 2009 Sep;39(9):694-9. doi: 10.1080/00498250903060077. PubMed PMID: 19555315.

18: Oertel R, Richter K, Trausch B, Berndt A, Gramatté T, Kirch W. Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum. J Chromatogr B Biomed Appl. 1994 Oct 14;660(2):353-63. PubMed PMID: 7866526.

19: Bogman K, Zysset Y, Degen L, Hopfgartner G, Gutmann H, Alsenz J, Drewe J. P-glycoprotein and surfactants: effect on intestinal talinolol absorption. Clin Pharmacol Ther. 2005 Jan;77(1):24-32. PubMed PMID: 15637528.

20: Weitschies W, Bernsdorf A, Giessmann T, Zschiesche M, Modess C, Hartmann V, Mrazek C, Wegner D, Nagel S, Siegmund W. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharm Res. 2005 May;22(5):728-35. Epub 2005 May 17. PubMed PMID: 15906167.